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ABSTRACT                        The oxidative stress and the released heme molecule of degrading red blood
cells during hemodialysis induce the expression of heme oxygenase 1 gene (HMOX1). The goal
of our study was to measure the expression of HMOX1 during dialysis and compare it with the
common oxidative markers. We established a cRT-PCR (competitive reverse transcriptase PCR)
method to measure the mRNA levels. The mRNA levels were calculated to the white blood cell
count respectively for each sample. We measured a 1-5-fold increase in the HMOX1 gene
expression after the dialysis session, which dropped back to the original value 48 hours after
the dialysis. The base level of HMOX1 mRNA of hemodialysed patients before dialysis was in
the range of normal controls. The changes in mRNA levels showed significant correlation with
the plasma hemoglobin (r=0.72, p<0.001) and plasma bilirubin (r=0.71, p<0.002) changes. We
found no correlation between the changes of mRNA levels and other biochemical markers
(GSH, GSSG). Our results suggest that the induced HMOX1 expression during hemodialysis is
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Oxidative stress is known to play an important role in the
etiology of numerous human conditions, including athero-
sclerosis, cerebral ischemia, and several neurodegenerative,
neuromuscular disorders and renal injury. Cellular antiox-
idants appear to be crucial for the reduction of ox-idative
stress and the prevention of associated pathology. Of the
known enzymatic antioxidant systems, perhaps the best
characterized are superoxide dismutases, catalases, and
glutathione peroxidase, which directly metabolize free radical
precursors (Coyle and Puttfracken 1993). A group of stress
proteins including heme oxygenase 1 are up regulated during
oxidative stress and ostensibly act to maintain the structural
and functional integrity of damaged proteins, and thus plays
cytoprotective role. Heme oxygenases catalyze the rate-
limiting step in heme degradation, resulting in the formation
of iron, carbon monoxide, and biliverdin, which is sub-
sequently converted to bilirubin by biliverdin reductase.
Heme is a tetrapyrole with a redox active iron center, and
functions as a co-factor for various proteins such as hemo-
globin, myoglobin, cytochromes, catalases (Balla et al. 1993;
Muller-Eberhard and Fraig 1993). In this role heme is
essential for many biological process including oxygen
transport and energy production. Tissue damage or cell injury
can destabilize heme-proteins and result in “free” hem, which
in turn can damage cellular components and disrupt cellular
function (Balla et al. 1991a, 1991b; Nath et al. 1995, 1998).
Heme itself promotes to the oxidative degradation of DNA
(Aft and Mueler 1983), proteins (Aft and Mueler 1984) and
amplifies the hydrogen peroxide mediated endothelial cell
dysfunction (Balla et al. 1993). The elimination of excess
“free” heme is done by the heme oxygenases (HOs). At
present three functional isoforms of HO are known (HO-1,
HO-2 and HO-3). HO-2 and HO-3 are constitutional form
while HO-1 is inducible by heme (Alam et al. 2002), and
various other physiological and non-physiological stimuli
such as hemin (Shibahara et al. 1978), inflammatory cy-
tokines (Rizzardini et al. 1993; Kutty et al. 1994), UV-
irradiation, heavy metals and arsenite (Keyse and Tyrrel
1989). The HO-1 obviously plays a cytoprotective role in
oxidative stress (Stocker 1990) and heme mediated injury
(Nath et al. 1995, 2000, 2001), which is also confirmed by
the knockout animal model (Poss and Tonegawa 1997).
Furthermore HO-1 has been implicated in many clinically
relevant disease states including atherosclerosis, transplanted
graft rejection (Avihingsanon et al. 2002), acute renal injury
(Schaaf et al. 2002; Yoneya et al. 2002), as well as others.
The hemodialysed uremic patients suffer from a periodic
oxidative stress (three times a week), which occurs due to the
cell shearing and hemolysis during HD. The considerable
amount of hem damages the vascular endothelium and
contributes to atherosclerosis of these patients. This raises the
question how the heme oxygenase reacts to this elevated
stress condition. The HO-1 gene expression had not been
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studied yet in uremic patients; therefore we wanted to
investigate the changes in HO-1 activity simultaneously with
the usual parameters of oxidative stress, and the correlation
of the two systems during HD. It is known that HO-1 is
expressed in monocytes, leucocytes and macrophages
(Shibahara et al. 1978) therefore we used blood samples for
the non-invasive monitoring of metabolites and HO-1 levels.
Since HO-1 induction is primarily regulated at the mRNA
level of HMOX1 gene transcription it was feasible to develop
a method for measuring the mRNA levels.
Materials and Methods
Seventeen patients with end stage renal disease (ESRD) on
regular hemodialysis (HD; 9 male and 8 female aged
14,9±3,1) were studied. The distribution of the original
nephrological diagnosis in the ESRD group were as follows
chronic pyelonephritis with reflux nephropathy 9, interstial
nephritis 2, membranoproliferate glomerulonephritis 3, focal
segmental glomerulosclerosis 2, rapidly progressive glo-
merulonephritis 1. All patients had been on antihypertensive
therapy with a combination of angiotensin converting en-
zyme inhibitor and calcium channel blocker because of
hypertension. The patients had been on 4-h bicarbonate HD
(3 times a week) for 1-5 years. HD was performed with
hemophan single-use dialyser. The blood flow rate was 200
ml/min and the dialysate flow rate was 500 ml/min. During
HD heparin was used as an anticoagulant, with initial dose
of 500 IU, followed by continuous infusion rate of 1000 IU/
h. The venous blood samples were collected before, immedi-
ately after HD and 48 hours following HD. For mRNA
separation 1ml native blood were collected and stabilized in
RNA/DNA stabilization Reagent for Blood/Bone Marrow
(Roche Diagnostics GmbH, Germany) for biochemical
assays 2-2 ml of EDTA and heparinised blood were collected.
Plasma hemoglobin, bilirubin and blood
carboxyhemoglobin, methemoglobin levels
For the assay of plasma hemoglobin and bilirubin contents,
heparinised plasma samples were diluted 1:40 (v/v) with 5
mmol L-1 PBS, pH 7.4, and measured spectrophotometrically
according to the method of Winterbourn (1979). Blood
carboxyhemoglobin concentration was also measured spec-
trophotometrically (OSM 3 Hemoximeter, Radiometer,
Coppenhagen).
Reduced and oxidized glutathione
Highly sensitive and specific determinations of total and
oxidized glutathione concentrations were made by com-
bining previously accepted standard methods (Németh and
Boda 1994).
For the assay of total glutathione concentration, 25 µl of
whole blood anticoagulated with EDTA was immediately
hemolyzed in 2.5 ml cold (4oC) 0.01 M potassium phosphate
buffer containing 5 mM EDTA, pH 7.5, and stored at –70oC
until further use. For analysis, 25 µl of hemolyzate was added
to the standard glutathione assay mixture (final volume 1 ml)
in the order indicated: DTNB (0.6 µmol), glutathione re-
ductase (10 µg) and NADPH (0.2 µmol). The combined
action of DTNB and NADPH in the presence of glutathione
reductase results in a reaction cycle, the rate of which
depends on the total concentration of GSH and GSSG
recorded spectrophotometrically at 412 nm during the first
6 min. For the determination of GSSG blood was hemolyzed
in the phosphate buffer described above previously supple-
mented with 0.02 mM N-ethylmaleimide (NEM). The reac-
tion of NEM with GSH results in the formation of a stable
complex, preventing GSH from participating in the enzy-
matic assay and from being oxidized to GSSG. As NEM is
an inhibitor of glutathione reductase, it was necessary to
separate it by gel filtration with Sephadex G-10 before further
analysis. The concentrations of the thiols were expressed
with reference to hemoglobin (hgb) determined by the
cyanmethemoglobin method.
RNA extraction and cRT-PCR experiments
mRNA was extracted from 1ml venous blood using mRNA
Isolation Kit for Blood/Bone Marrow (Roche Diagnostics
GmbH, Mannheim, Germany). To avoid loss of mRNA due
Figure 1. Part of HMOX1 CDS from exon 3 to 5, HMOX1-T3 and
HMOX1-mut were used to create a PCR product from which we
transcribed our control RNA, which sequence only differs in a 20bp
deletion from wild type HMOX1 mRNA. The mRNA and control RNA
was reverse transcribed and consecutively amplified by the same
primers HMOX1-F and HMOX1-R. Primers were designed to span exon
boundaries to avoid binding at genomic DNA level.
before H D after H D 48 hours after H D
1x 3x 9x 27x 1x 3x 9x 27x 1x 3x 9x 27x
Figure 2. HMOX1 mRNA expressions of a patient with oxidative
hemolysis; before, after and 48 hours after HD. The 1, 3, 9, 27x
dilutions of control RNA was reverse transcribed with equal amounts
of mRNA and amplified by the same PCR primers. The arrows show
the concentrations where mRNA concentration is equal to the control
RNA concentration.
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to limited glass surface or ligands we scaled the separation
as we were separating 1.5ml blood samples. Competitive RT-
PCR was used to identify the expression of heme oxygenase
1 gene (HMOX1). The competitor RNA was created by in
vitro mutagenesis and transcription with T3 RNA polymerase
(Fermentas AB, Vilnius, Lithuania) according to Waha et al.
(1998). The primers to generate the competitor were as
follows: HMOX1-T3: 5’ AAT TAA CCC TCA CTA AAG
GGA GAC GTT TCT GCT CAA CAT CCA GCT C 3’ and
HMOX1-mut: 5’ CCT GGG AGC GGG TGT TGA GTG
GGG GGC AGA ATC TTG CAC TTT G 3’. First strand
cDNA was generated using RevertAidTM First Strand cDNA
Synthesis Kit (Fermentas AB, Vilnius, Lithuania) using
specific primer of HMOX1-R. The specific oligonucleotide
primers used for the PCR reaction were designed to span
exon boundaries thus binding only at the cDNA level (Fig.
1). The PCR amplification were carried out by the following
program: initial denaturation at 94ºC for 5 min followed by
25 cycles of denaturation at 94ºC for 20 sec, annealing at
61ºC for 30 sec and extension at 72°C for 20 sec followed
by a final extension at 72°C for 10 min. The primers were as
follows: HMOX1-F: 5’ CGT TTC TGC TCA ACA TCC
AGC TC 3’ and HMOX1-R: 5’ CCT GGG AGC GGG TGT
TGA GTG 3’. The amplified cDNAs were examined on 6%
polyacrylamide gel and stained with ethidium bromide. The
target heme oxygenase 1 band was estimated by the ratio to
the competitor by densitometry (AlphaImagerTM, AlphaEase
5.5). The HMOX1 mRNA concentrations were expressed
with reference to white blood cell count; since we hadn’t
calculated the copy number of our control RNA they rep-
resent relative values (we used the same dilutions of control
RNA). Since control RNA and mRNA was handled in the
same tubes together their relative ratio remained the same
throughout the whole process.
Figure 3. HMOX1 mRNA expression A) in patients with low HMOX1 levels B) in patients with elevated HMOX1 expression.
Figure 4. Changes in metabolite levels in the patients (n=10) with
low HMOX1 mRNA levels before HD.
Figure 5. Changes in metabolite levels in the patients (n=7) with




Clinical data on the patients are reported as means ± SD (x
± SD), whereas results of biochemical analyses are shown in
figures as means ± standard errors (x ± SEM). Statistical
analyses were performed with the Tukey test, Student’s t-test,
and correlation analysis. The significance level for all tests
was taken as p=0.05.
Results
We established a cRT-PCR method for the measurement of
HMOX1 mRNA levels from blood (Fig. 2). We measured the
plasma hemoglobin, plasma bilirubin, carboxyhemoglobin,
methemoglobin, GSH and GSSG levels from venous blood
samples.
We divided our patients into two groups; in the first group
of patients (n=10) the HMOX1 mRNA levels were low
before HD. In this group we measured a 1-5-fold increase
(p=0.0014) in the HMOX1 gene expression after HD, which
dropped back to the original value 48 hours after HD (Fig.
3A). The plasma hemoglobin and bilirubin levels increased
after HD and their value dropped back 48 hours after HD
(Fig. 4). In the second group there was already a higher level
of HMOX1 mRNA expression, in these patients the HMOX1
was not induced further after HD (Fig. 3B). In this group of
patients the plasma bilirubin levels increased after HD, and
the plasma hemoglobin levels remained the same after HD
but both of them decreased 48 hours later (Fig. 5). In the two
groups there were no significant changes in the GSH and
GSSG levels (Fig. 4,5).
The mRNA levels varied greatly between individuals
therefore we calculated the quotient of after HD/before HD
of the measured metabolite and HMOX1 mRNA levels,
which gives the effect of HD on these parameters.
We found significant correlation between the changes of
HMOX1 mRNA levels and plasma hemoglobin (r=0.72,
p<0.001) levels, plasma bilirubin (r=0.71, p<0.002) levels
compared before and after HD (Table 1, Fig. 6). We found
no significant correlation between the changes of HMOX1
mRNA levels and changes in the measured oxidative stress
markers (Table 1).
Discussion
The average duration of a session for a chronic uremic patient
is 4 hours. This time is enough to induce HO-1. Since HO-1
is induced at the mRNA levels the earliest response to the
HO-1 induction can be monitored by the measurement of
mRNA levels. For the quantitative mRNA analysis we had
chosen a cRT-PCR method. This PCR based technique
permits the precise analysis from small amount of samples
(Kozbor et al. 1993; Waha et al. 1998). The analysis of
HMOX1 mRNA from blood samples is noninvasive and
easily conducted at the hemodialysed patients. This also
gives the advantage that the target tissue (blood) is the same
for the measurement of mRNA and other parameters.
In the patients who had already elevated HMOX1 expres-
sion before HD the HO-1 catabolyzed the “free” hem and
was not further induced. In the patients who had low mRNA
levels before HD the HMOX1 was induced by the under-
going hemolysis. The great differences between the base
HMOX1 mRNA levels in the patients can be explained by the
different redox or inflammatory states (Nath et al. 2001).
Due to the shearing of cells and hemolysis during HD the
plasma hemoglobin levels increased, which according to our
data and the literature (Nath et al. 2000, 2001; Alam et al.
2002) induced HO-1. In those patients where no marked
hemolysis occurred there was no significant HO-1 induction.
We did not find any significant changes in the GSH and
GSSG levels due to the undergoing HD that confirms our
previous data (Túri et al. 1991) and suggest that the glu-
tathione system is not elevated in these conditions.
The effect of HD could be best monitored by the mea-
sured parameters after HD and before HD.
The significant correlation between the changes of
hemoglobin (inductor) and bilirubin (sequential product)
levels with HMOX1 mRNA levels before and after HD
shows that hemoglobin induced HO-1, and the induced HO-1
catabolyzed the hem-molecules.
Since we found no correlation between HMOX1 gene
Figure 6. Correlation of the changes in HMOX1 mRNA levels with
the changes in hemoglobin, bilirubin levels in all patients (n=17)
before and after HD.
Table 1. Correlation between the changes of biochemical
parameters and HMOX1 mRNA levels (r).
biochemical markers HMOX1 mRNA before HD/after HD
Plasma hemoglobin 0.72; p<0.001
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expression and the common oxidative markers (GSH, GSSG)
our results suggest that the induced HMOX1 expression
during hemodialysis is primarily due to the occurring hemol-
ysis.
By our study it is clear that this group of patients has an
inducible HMOX1 gene that responds to the stimuli of its
substrate and is functionally intact (the induced HMOX1
expression leads to elevated bilirubin level). As we have no
hemodialysed control people we don’t know whether the
induction due to hemolysis in our patients is comparable to
normal people. Therefore further studies are needed to
investigate a promoter polymorphism – which directly alters
the inducibility of HMOX1 gene (Yamada et al. 2001)– on
a control population and hemodialysed patients to see
whether the HO-1 plays a role in the pathomechanism of
vascular damage in uremic patients.
References
Aft RL, Mueller GC (1983) Hemin-mediated DNA strand scission. J Biol
Chem 258:12069-12072.
Aft RL, Mueller GC (1984) Hemin-mediated oxidative degradation of
proteins. J Biol Chem 259:301-305.
Alam J, Killeen E, Gong P, Naquin R, Hu B, Stewart D, Ingelfinger JR,
Nath KA (2002) Heme activates the heme oxygenase-1 gene in renal
epithelial cells by stabilizing Nrf2. Am J Physiol Renal Physiol
284:743-752.
Avihingsanon Y, Ma N, Csizmadia E, Wang C, Pavlakis M, Giraldo M,
Strom TB, Soares MP, Ferran C (2002) Expression of protective genes
in human renal allografts: a regulatory response to injury associated
with graft rejection. Transplantation 73:1079-1085.
Balla G, Jacob HS, Eaton JW, Belcher JD, Vercellotti GM (1991a) Hemin:
a possible physiological mediator of low density lipoprotein oxidation
and endothelial injury. Arterioscler Thromb 11:1700-1711.
Balla G, Vercellotti GM, Muller-Eberhard U, Eaton J, Jacob HS (1991b)
Exposure of endothelial cells to free heme potentiates damage mediat-
ed by granulocytes and toxic oxygen species. Lab Invest 64: 648-655.
Balla J, Jacob HS, Balla G, Nath K, Eaton JW, Vercellotti GM (1993)
Endothelial-cell heme uptake from heme proteins: induction of
sensitization and desensitization to oxidant damage. Proc Natl Acad
Sci USA 90:9285-9289.
Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neuro-
degenerative disorders. Science 262:689-695.
Jenkins JK, Huang H, Ndebele K, Salahudeen AK (2001) Vitamin E inhibits
renal mRNA expression of COX II, HO I, TGFbeta, and osteopontin
in the rat model of cyclosporine nephrotoxicity. Transplantation
71:331-334.
Johnson DA, Osaki S, Frieden E (1967) A micromethod for the deter-
mination of ferroxidase (Coeruloplasmine) in human serum. Clin
Chem 13:142-150.
Keyse SM, Tyrrell RM (1989) Heme oxygenase is the major 32-kDa stress
protein induced in human skin fibroblasts by UVA radiation, hydrogen
peroxide, and sodium arsenite. Proc Natl Acad Sci USA 86:99-103.
Kozbor D, Hyjek E, Wiaderkiewicz R, Wang Z, Wang M, Loh E (1993)
Competitor mRNA fragments for quantitation of cytokine specific
transcripts in cell lysates. Mol Immunol 30:1-7.
Kutty RK, Naginemi GN, Kutty G, Hooks JJ, Chader GJ, Wiggert B (1994)
Increased expression of heme oxygenase-1 in human retinal pigment
epithelial cells by transforming growth factor-beta. J Cell Physiol
159:371-378.
Muller-Eberhard U, Fraig M (1993) Bioactivity of heme and its con-
tainment. Am J Hematol 42:59-62.
Nath KA, Balla J, Croatt AJ, Vercellotti GM (1995) Heme protein-mediated
renal injury: a protective role for 21-aminosteroids in vitro and in vivo.
Kidney Int 47:592-602.
Nath KA, Grande JP, Croatt AJ, Likely S, Hebbel RP, Enright H (1998)
Intracellular targets in heme protein-induced renal injury. Kidney Int
53:100-111.
Nath KA, Haggard JJ, Croatt AJ, Grande JP, Poss KD, Alam J (2000) The
indispensability of heme oxygenase-1 in protecting against acute heme
protein-induced toxicity in vivo. Am J Pathol 156:1527-1535.
Nath KA, Vercellotti GM, Grande JP, Miyoshi H, Paya CV, Manivel JC,
Haggard JJ, Croatt AJ, Payne WD, Alam J (2001) Heme protein-
induced chronic renal inflammation: suppressive effect of induced
heme oxygenase-1. Kidney Int 59:106-117.
Németh I, Boda D (1994) Blood glutathione redox ratio as a parameter of
oxidative stress in premature infants with IRDS. Free Rad Biol Med
16:347-353.
Poss KD, Tonegawa S (1997) Reduced stress defense in heme oxygenase
1-deficient cells. Proc Natl Acad Sci USA 94:10925-10930.
Rizzardini M, Terao M, Falciani F, Cantoni L (1993) Cytokine induction
of haem oxygenase mRNA in mouse liver. Interleukin 1 transcrip-
tionally activates the haem oxygenase gene. J Biochem 290:343-347.
Schaaf GJ, Maas RF, de Groene EM, Fink-Gremmels J (2002) Management
of oxidative stress by heme oxygenase-1 in cisplatin-induced toxicity
in renal tubular cells. Free Radic Res 36:835-43.
Túri S, Németh I, Vargha I, Matkovics B, Dobos É (1991) Erythrocyte
defense mechanisms against free oxygen radicals in haemodialysed
uraemic children. Pediatr Nephrol 5:179-183.
Shibahara S, Yoshida T, Kikuchi G (1978) Induction of heme oxygenase
by hemin in cultured pig alveolar macrophages. Arch Biochem
Biophys 188:243-250.
Stocker R (1990) Induction of haem oxygenase as a defence against
oxidative stress. Free Radic Res Commun 9:101-112.
Yamada N, Yamaya M, Okinaga S, Nakayama K, Sekizawa K, Shibahara
S, Sasaki H (2001) Microsatellite polymorphism in the heme
oxygenase-1 gene promoter is associated with susceptibility to
emphysema. Am J Hum.Genet 66:187-195, 2000. Note: Erratum: Am
J Hum Genet 68:1542.
Yoneya R, Nagashima Y, Sakaki K, Hagiwara K, Teraoka H, Ozasa H,
Horikawa S (2002) Hemolysate pretreatment ameliorates ischemic
acute renal injury in rats. Nephron 92:407-413.
Waha A, Watzka M, Koch A, Pietsch T, Przkora R, Peters N, Wiestler OD,
von Deimling A (1998) A rapid and sensitive protocol for competitive
reverse transcriptase (cRT) PCR analysis of cellular genes. Brain Pathol
8:13-18.
Winterbourn CC (1979) Oxidative reactions of hemoglobin. Meth Enzymol
186:265-272.
